financetom
Business
financetom
/
Business
/
China's XPeng reports Q3 revenue jump on strong EV deliveries
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
China's XPeng reports Q3 revenue jump on strong EV deliveries
Nov 17, 2025 1:38 AM

Overview

* XPeng ( XPEV ) Q3 revenue rises 101.8% yr/yr, driven by higher vehicle deliveries

* Gross margin improves to 20.1%, up 4.8 percentage points yr/yr

* Net loss narrows significantly from last year, reflecting operational improvements

Outlook

* XPeng ( XPEV ) expects Q4 vehicle deliveries between 125,000 and 132,000 units

* XPeng ( XPEV ) forecasts Q4 revenue between RMB21.5 bln and RMB23.0 bln

Result Drivers

* HIGHER DELIVERIES - Co attributes revenue growth to increased vehicle deliveries, particularly from new models

* COST CONTROL - Gross margin improvement linked to effective cost control and technology-related revenue streams

* TECHNICAL SERVICES - Increased revenues from after-sales services and technical R&D services contributed to results

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 RMB

Revenue 20.38

bln (US$

2.86

billion)

Q3 -RMB

Adjusted 0.16

Earnings

Per ADS

Q3 -RMB 150

Adjusted mln

Net

Income

Q3 Gross 20.10%

Margin

Q3 -RMB 520

Adjusted mln

Income

from

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the auto & truck manufacturers peer group is "buy"

* Wall Street's median 12-month price target for Xpeng Inc ( XPEV ) is $28.00, about 10.7% above its November 14 closing price of $25.01

* The stock recently traded at 156 times the next 12-month earnings vs. a P/E of 2,391 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Philippines to pay 19% tariff, Trump says
Philippines to pay 19% tariff, Trump says
Jul 22, 2025
WASHINGTON (Reuters) -U.S. President Donald Trump said on Tuesday that the Philippines will pay a 19% tariff rate following the conclusion of a trade deal with the United States. It was a beautiful visit, and we concluded our Trade Deal, whereby The Philippines is going OPEN MARKET with the United States, and ZERO Tariffs. The Philippines will pay a 19%...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Vertex Pharmaceuticals Gets Marketing Authorization for Cystic Fibrosis Treatment in Canada
Vertex Pharmaceuticals Gets Marketing Authorization for Cystic Fibrosis Treatment in Canada
Jul 22, 2025
01:41 PM EDT, 07/22/2025 (MT Newswires) -- Vertex Pharmaceuticals ( VRTX ) said Tuesday its cystic fibrosis treatment Alyftrek has received marketing authorization from Health Canada. The once-daily triple combination therapy is approved for patients aged 6 years and older with at least one F508del mutation or another responsive cystic fibrosis transmembrane conductance regulator, or CFTR, mutation. About 3,800 people...
Danaher lifts annual profit forecast on pharma demand, China recovery
Danaher lifts annual profit forecast on pharma demand, China recovery
Jul 22, 2025
July 22 (Reuters) - Life sciences firm Danaher ( DHR ) raised its annual profit forecast on Tuesday, banking on steady demand for bioprocessing from its pharmaceutical clients and a recovery in China. Danaher ( DHR ), which provides tools and technologies that help pharmaceutical companies develop and make drugs, said demand from the industry remains strong, with robust number...
Copyright 2023-2026 - www.financetom.com All Rights Reserved